Cargando…
Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study
It has not yet been determined whether chronic exposure to relatively low doses of pioglitazone increases risk of bladder cancer. We aimed to assess the risk of bladder cancer associated with pioglitazone in Korean patients. This was a retrospective cohort study of diabetic patients who had ≥ 2 clin...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Korean Academy of Medical Sciences
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924003/ https://www.ncbi.nlm.nih.gov/pubmed/24550651 http://dx.doi.org/10.3346/jkms.2014.29.2.238 |
_version_ | 1782303687995031552 |
---|---|
author | Jin, Sang-Man Song, Sun Ok Jung, Chang Hee Chang, Jin-Sun Suh, Sunghwan Kang, Seung Min Jung, Inkyung Park, Cheol-Young Kim, Jae Hyeon Cho, Jae Hyoung Lee, Byung-Wan |
author_facet | Jin, Sang-Man Song, Sun Ok Jung, Chang Hee Chang, Jin-Sun Suh, Sunghwan Kang, Seung Min Jung, Inkyung Park, Cheol-Young Kim, Jae Hyeon Cho, Jae Hyoung Lee, Byung-Wan |
author_sort | Jin, Sang-Man |
collection | PubMed |
description | It has not yet been determined whether chronic exposure to relatively low doses of pioglitazone increases risk of bladder cancer. We aimed to assess the risk of bladder cancer associated with pioglitazone in Korean patients. This was a retrospective cohort study of diabetic patients who had ≥ 2 clinic visits between November 2005 and June 2011 at one of four tertiary referral hospitals in Korea. A prevalent case-control analysis nested within the cohort was conducted to further adjust confounders. A total of 101,953 control patients and 11,240 pioglitazone-treated patients were included, in which there were 237 and 30 cases of incidental bladder cancer (64.9 and 54.9 per 100,000 person-years; age, sex-adjusted HR 1.135, 95% confidence interval [CI] 0.769-1.677), respectively. In the prevalent case-control analysis nested within the cohort, use of pioglitazone for a duration of > 6 months, but not ever use of pioglitazone, was associated with an increased rate of bladder cancer as compared to never use of pioglitazone. In conclusion, we failed to exclude the possible association between use of pioglitazone for a duration of > 6 months and bladder cancer. GRAPHICAL ABSTRACT: [Image: see text] |
format | Online Article Text |
id | pubmed-3924003 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2014 |
publisher | The Korean Academy of Medical Sciences |
record_format | MEDLINE/PubMed |
spelling | pubmed-39240032014-02-18 Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study Jin, Sang-Man Song, Sun Ok Jung, Chang Hee Chang, Jin-Sun Suh, Sunghwan Kang, Seung Min Jung, Inkyung Park, Cheol-Young Kim, Jae Hyeon Cho, Jae Hyoung Lee, Byung-Wan J Korean Med Sci Original Article It has not yet been determined whether chronic exposure to relatively low doses of pioglitazone increases risk of bladder cancer. We aimed to assess the risk of bladder cancer associated with pioglitazone in Korean patients. This was a retrospective cohort study of diabetic patients who had ≥ 2 clinic visits between November 2005 and June 2011 at one of four tertiary referral hospitals in Korea. A prevalent case-control analysis nested within the cohort was conducted to further adjust confounders. A total of 101,953 control patients and 11,240 pioglitazone-treated patients were included, in which there were 237 and 30 cases of incidental bladder cancer (64.9 and 54.9 per 100,000 person-years; age, sex-adjusted HR 1.135, 95% confidence interval [CI] 0.769-1.677), respectively. In the prevalent case-control analysis nested within the cohort, use of pioglitazone for a duration of > 6 months, but not ever use of pioglitazone, was associated with an increased rate of bladder cancer as compared to never use of pioglitazone. In conclusion, we failed to exclude the possible association between use of pioglitazone for a duration of > 6 months and bladder cancer. GRAPHICAL ABSTRACT: [Image: see text] The Korean Academy of Medical Sciences 2014-02 2014-01-28 /pmc/articles/PMC3924003/ /pubmed/24550651 http://dx.doi.org/10.3346/jkms.2014.29.2.238 Text en © 2014 The Korean Academy of Medical Sciences. http://creativecommons.org/licenses/by-nc/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Original Article Jin, Sang-Man Song, Sun Ok Jung, Chang Hee Chang, Jin-Sun Suh, Sunghwan Kang, Seung Min Jung, Inkyung Park, Cheol-Young Kim, Jae Hyeon Cho, Jae Hyoung Lee, Byung-Wan Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study |
title | Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study |
title_full | Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study |
title_fullStr | Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study |
title_full_unstemmed | Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study |
title_short | Risk of Bladder Cancer among Patients with Diabetes Treated with a 15 mg Pioglitazone Dose in Korea: A Multi-Center Retrospective Cohort Study |
title_sort | risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in korea: a multi-center retrospective cohort study |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3924003/ https://www.ncbi.nlm.nih.gov/pubmed/24550651 http://dx.doi.org/10.3346/jkms.2014.29.2.238 |
work_keys_str_mv | AT jinsangman riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy AT songsunok riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy AT jungchanghee riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy AT changjinsun riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy AT suhsunghwan riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy AT kangseungmin riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy AT junginkyung riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy AT parkcheolyoung riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy AT kimjaehyeon riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy AT chojaehyoung riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy AT leebyungwan riskofbladdercanceramongpatientswithdiabetestreatedwitha15mgpioglitazonedoseinkoreaamulticenterretrospectivecohortstudy |